139 related articles for article (PubMed ID: 22302553)
21. Effect of partial targeted N-butyl-cyano-acrylate embolization in brain AVM.
Meisel HJ; Mansmann U; Alvarez H; Rodesch G; Brock M; Lasjaunias P
Acta Neurochir (Wien); 2002 Sep; 144(9):879-87; discussion 888. PubMed ID: 12376769
[TBL] [Abstract][Full Text] [Related]
22. Arteriovenous malformations: epidemiology and clinical presentation.
Laakso A; Hernesniemi J
Neurosurg Clin N Am; 2012 Jan; 23(1):1-6. PubMed ID: 22107853
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for hemorrhagic presentation in patients with dural arteriovenous fistulae.
Singh V; Smith WS; Lawton MT; Halbach VV; Young WL
Neurosurgery; 2008 Mar; 62(3):628-35; discussion 628-35. PubMed ID: 18425010
[TBL] [Abstract][Full Text] [Related]
24. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort.
Lhatoo SD; Johnson AL; Goodridge DM; MacDonald BK; Sander JW; Shorvon SD
Ann Neurol; 2001 Mar; 49(3):336-44. PubMed ID: 11261508
[TBL] [Abstract][Full Text] [Related]
25. The natural history of cavernous malformations: a prospective study of 68 patients.
Moriarity JL; Wetzel M; Clatterbuck RE; Javedan S; Sheppard JM; Hoenig-Rigamonti K; Crone NE; Breiter SN; Lee RR; Rigamonti D
Neurosurgery; 1999 Jun; 44(6):1166-71; discussion 1172-3. PubMed ID: 10371615
[TBL] [Abstract][Full Text] [Related]
26. Complications of cerebral arteriovenous malformation embolization: multivariate analysis of predictive factors.
Ledezma CJ; Hoh BL; Carter BS; Pryor JC; Putman CM; Ogilvy CS
Neurosurgery; 2006 Apr; 58(4):602-11; discussion 602-11. PubMed ID: 16575323
[TBL] [Abstract][Full Text] [Related]
27. Long-term natural history of incidentally discovered cavernous malformations in a single-center cohort.
Moore SA; Brown RD; Christianson TJ; Flemming KD
J Neurosurg; 2014 May; 120(5):1188-92. PubMed ID: 24628608
[TBL] [Abstract][Full Text] [Related]
28. Multiple intracranial cavernous malformations: clinical features and treatment.
Zhao Y; Du GH; Wang YF; Wu JS; Xie LQ; Mao Y; Zhou LF
Surg Neurol; 2007 Nov; 68(5):493-9; discussion 499. PubMed ID: 17707490
[TBL] [Abstract][Full Text] [Related]
29. Racial/Ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients.
Kim H; Sidney S; McCulloch CE; Poon KY; Singh V; Johnston SC; Ko NU; Achrol AS; Lawton MT; Higashida RT; Young WL;
Stroke; 2007 Sep; 38(9):2430-7. PubMed ID: 17673729
[TBL] [Abstract][Full Text] [Related]
30. Cerebral cavernous malformations and pregnancy: hemorrhage risk and influence on obstetrical management.
Witiw CD; Abou-Hamden A; Kulkarni AV; Silvaggio JA; Schneider C; Wallace MC
Neurosurgery; 2012 Sep; 71(3):626-30; discussion 631. PubMed ID: 22710379
[TBL] [Abstract][Full Text] [Related]
31. Cavernous Malformation Hemorrhagic Presentation at Diagnosis Associated with Low 25-Hydroxy-Vitamin D Level.
Flemming KD; Kumar S; Brown RD; Singh RJ; Whitehead K; McCreath L; Lanzino G
Cerebrovasc Dis; 2020; 49(2):216-222. PubMed ID: 32348981
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal risk of intracranial hemorrhage in patients with arteriovenous malformation of the brain within a defined population.
Halim AX; Johnston SC; Singh V; McCulloch CE; Bennett JP; Achrol AS; Sidney S; Young WL
Stroke; 2004 Jul; 35(7):1697-702. PubMed ID: 15166396
[TBL] [Abstract][Full Text] [Related]
33. Cause is the main predictor of outcome in patients with pontine hemorrhage.
Rabinstein AA; Tisch SH; McClelland RL; Wijdicks EF
Cerebrovasc Dis; 2004; 17(1):66-71. PubMed ID: 14530640
[TBL] [Abstract][Full Text] [Related]
34. Use of antithrombotic agents in patients with intracerebral cavernous malformations.
Flemming KD; Link MJ; Christianson TJ; Brown RD
J Neurosurg; 2013 Jan; 118(1):43-6. PubMed ID: 22998055
[TBL] [Abstract][Full Text] [Related]
35. Hemorrhage risk and clinical features of multiple intracranial arteriovenous malformations.
Boone CE; Caplan JM; Yang W; Ye X; Colby GP; Coon AL; Tamargo RJ; Huang J
J Clin Neurosci; 2016 Jan; 23():51-57. PubMed ID: 26461910
[TBL] [Abstract][Full Text] [Related]
36. Characterization of radiation-induced cavernous malformations and comparison with a nonradiation cavernous malformation cohort.
Cutsforth-Gregory JK; Lanzino G; Link MJ; Brown RD; Flemming KD
J Neurosurg; 2015 May; 122(5):1214-22. PubMed ID: 25699412
[TBL] [Abstract][Full Text] [Related]
37. Intracranial hemorrhage from moyamoya disease during pregnancy and puerperium.
Liu XJ; Zhang D; Wang S; Zhao YL; Ye X; Rong W; Yong C; Kang S; Zhao JZ
Int J Gynaecol Obstet; 2014 May; 125(2):150-3. PubMed ID: 24552854
[TBL] [Abstract][Full Text] [Related]
38. Temporal clustering of hemorrhages from untreated cavernous malformations of the central nervous system.
Barker FG; Amin-Hanjani S; Butler WE; Lyons S; Ojemann RG; Chapman PH; Ogilvy CS
Neurosurgery; 2001 Jul; 49(1):15-24; discussion 24-5. PubMed ID: 11440436
[TBL] [Abstract][Full Text] [Related]
39. The Influence of Physical Activity on Cavernous Malformation Hemorrhage.
Joseph NK; Kumar S; Lanzino G; Flemming KD
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104629. PubMed ID: 32147026
[TBL] [Abstract][Full Text] [Related]
40. Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations.
Zuurbier SM; Hickman CR; Rinkel LA; Berg R; Sure U; Al-Shahi Salman R;
Stroke; 2022 Aug; 53(8):2521-2527. PubMed ID: 35410492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
